Our signature provides potential targets for targeted therapy of pyroptosis, especially CASP1 and GZMB. At present, pyroptosis has been considered for use in anti-tumor therapy, and our research suggests that pyroptosis combined with immunotherapy to improve the prognosis of patients may be an effective treatment direction. Here, GZMB is linked to neoplasm.